<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20190309042989N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2019-04-19</date_registration>
      <primary_sponsor>Artesh University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of the effect of intra-articular hypertonic saline, intra-articular HIALGAN and physiotherapy in patients with knee arthritis</public_title>
      <acronym></acronym>
      <scientific_title>Comparisonof the effectiveness of intra-articular injection of hypertonic saline, intra-articular injection of HIALGAN and knee physiotherapy in pain and function of patients with knee osteoarthritis</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2019-05-05</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>90</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/38223</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Randomization description: Patients with knee osteoarthritis will be recruited from the waiting list of an outpatient Department of Physical Medicine and Rehabilitation at Imam Reza Hospital. The Hospital is a large referral subspecialty center in Tehran affiliated withَ Artesh University of Medical Sciences. We are going to use block randomization with variable block size to provide four samples of equal size and patients are assigned to one of the arms using random blocks (90 samples are included in the study and divided into 3 groups with equal number, the first group :30 samples underwent intra-articular injection of hyper-saline, the second group : 30 samples underwent HYALGAN intra-articular injection and the third group: 30 samples underwent 10-session physiotherapy.). Random numbers will be generated with a computer in an independent statistical office, Blinding description: Due to different treatments and the number of different treatment sessions in each patient group, the patients and physician( was responsible to prescribing and explaining the treatment) was not blinded .
The person responsible for evaluating the patients with the pre and post questionnaire (who was the main researcher ) had no information on the treatment process and the patient group, so that the questionnaire was completed before the determination of the treatment method and after beginning of the treatment, every questionnaire depending on treatment method, a code ( 1. 2 or 3 ) is assigned and was in charge for re-evaluation.
After completion of the questionnaires, it is available to the data analyst and analyzed using the same allocation code to each data group.</study_design>
      <phase>3</phase>
      <hc_freetext>Knee osteoarthritis.</hc_freetext>
      <i_freetext>Intervention 1: First intervention group: Intra-articular injection of 5cc from Hypertonic Saline solution 5%(solution with a concentration of sodium chloride) at one time .Hypersalin brand medication from Shahid Ghazi pharmaceutical company. The method of intra-articular injection of the knee is determined according to the common methods and the amount of access to joint space in the plane radiography (inferomedial or medial, lateral approach). Prescribing 500 mg acetaminophen for use in pain situations and prescribing strengthening exercise for Quadriceps, hip adductors and hip abductors and stretching exercise for calf and hamstring muscles. Intervention 2: Second intervention group:  intra-articular injection of 2 cc from HYALGAN (Pre-filled syringe for intra-articular use , contain 20 milligram Hyaluronic acid sodium salt, with 2 miligram volume, From Fidia-Italy pharmaceutical company)inject 3 times with 1 week interval . The method of intra-articular injection of the knee is determined according to the common methods and the amount of access to joint space in the plane radiography (inferomedial or medial, lateral approach) .Prescribing 500 mg acetaminophen for use in pain situations and prescribing strengthening exercise for Quadriceps, hip adductors and hip abductors and stretching exercise for calf and hamstring muscles. Intervention 3: Control group: Knee physiotherapy involves using an infrared device for 20 minutes at a distance of 1 m from the body and perpendicularly,  using a transcutaneous electrical nerve stimulation (TENS) device for 20 minutes (with a high TENS protocol that includes a frequency of 100 to 150 Hz , A pulse duration of 150 microseconds and at tolerance level) and the use of an ultrasound device for 3 to 5 minutes (1 MHz frequency, 1.5 Watts per square centimeter and palsed protocol).Prescribing 500 mg acetaminophen for use in pain situations and prescribing strengthening exercise for Quadriceps, hip adductors and hip abductors and stretching exercise for calf and hamstring muscles.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is Need to make a decision at the University Research Council</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr. Ensieh Taftian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Emam Reza Hospital , Etemadzade Ave. ,Fatemi Blvd.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1411718541</zip>
        <telephone>+98 21 6653 5399</telephone>
        <email>ensieh.taftian@gmail.com</email>
        <affiliation>Artesh University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Ensieh Taftian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Emam Reza Hospital,  Etemadzade Ave., West Fatemi Blvd.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1411718541</zip>
        <telephone>+98 21 6653 5399</telephone>
        <email>ensieh.taftian@gmail.com</email>
        <affiliation>Artesh University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>ACR criteria (age more than 50 years old / cryptasion or morning stiffness less than 30 minutes / presence of radiographic evidence / presence of symptoms for more than three months)
K-L radiographic criteria :  grade 2-4</inclusion_criteria>
      <agemin>50 years</agemin>
      <agemax>80 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patient dissatisfaction
Other joint arthritis in the knee joint including rheumatoid arthritis and gout or systemic neuromuscular disorders such as Myasthenia Gravis, Eton-Lambert syndrome and ALS.
History of total Knee arthroplasty
History of fracture in the knee bones
Intra-articular corticosteroid injection over the past 2 weeks, history of hyaluronic acid injection or proletherapy over the past one year
Any contraindication for intra-articular injection such as thrombocytopenia , coagulation disorder, joint infections, skin infections at the injection site
Dysfunction of the lower extremity due to neurological or internal diseases such as stroke, traumatic brain injury, and diabetic foot disease
Severe knee joint effusion
BM I&gt; 35
Acute exacerbation of knee pain (less than 1 month)</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M17</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Osteoarthritis of knee</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Devices</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>First intervention group: Intra-articular injection of 5cc from Hypertonic Saline solution 5%(solution with a concentration of sodium chloride) at one time .Hypersalin brand medication from Shahid Ghazi pharmaceutical company. The method of intra-articular injection of the knee is determined according to the common methods and the amount of access to joint space in the plane radiography (inferomedial or medial, lateral approach). Prescribing 500 mg acetaminophen for use in pain situations and prescribing strengthening exercise for Quadriceps, hip adductors and hip abductors and stretching exercise for calf and hamstring muscles.</i_keyword>
      <i_keyword>Second intervention group:  intra-articular injection of 2 cc from HYALGAN (Pre-filled syringe for intra-articular use , contain 20 milligram Hyaluronic acid sodium salt, with 2 miligram volume, From Fidia-Italy pharmaceutical company)inject 3 times with 1 week interval . The method of intra-articular injection of the knee is determined according to the common methods and the amount of access to joint space in the plane radiography (inferomedial or medial, lateral approach) .Prescribing 500 mg acetaminophen for use in pain situations and prescribing strengthening exercise for Quadriceps, hip adductors and hip abductors and stretching exercise for calf and hamstring muscles.</i_keyword>
      <i_keyword>Control group: Knee physiotherapy involves using an infrared device for 20 minutes at a distance of 1 m from the body and perpendicularly,  using a transcutaneous electrical nerve stimulation (TENS) device for 20 minutes (with a high TENS protocol that includes a frequency of 100 to 150 Hz , A pulse duration of 150 microseconds and at tolerance level) and the use of an ultrasound device for 3 to 5 minutes (1 MHz frequency, 1.5 Watts per square centimeter and palsed protocol).Prescribing 500 mg acetaminophen for use in pain situations and prescribing strengthening exercise for Quadriceps, hip adductors and hip abductors and stretching exercise for calf and hamstring muscles.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain intensity based on the Visual Analogue Scale. Timepoint: Measuring pain intensity before the intervention, 1 month, 3 months and 6 months after the end of the intervention. Method of measurement: Visual Analogue Scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Symptoms. Timepoint: Before the intervention, 1 month, 3 months and 6 months after the end of the intervention. Method of measurement: Knee injury and Osteoarthritis Outcome Score (KOOS).</sec_outcome>
      <sec_outcome>Pain. Timepoint: Before the intervention, 1 month, 3 months and 6 months after the end of the intervention. Method of measurement: Knee injury and Osteoarthritis Outcome Score (KOOS).</sec_outcome>
      <sec_outcome>Function, daily living. Timepoint: Before the intervention, 1 month, 3 months and 6 months after the end of the intervention. Method of measurement: Knee injury and Osteoarthritis Outcome Score (KOOS).</sec_outcome>
      <sec_outcome>Function, sports and recreational activities. Timepoint: Before the intervention, 1 month, 3 months and 6 months after the end of the intervention. Method of measurement: Knee injury and Osteoarthritis Outcome Score (KOOS).</sec_outcome>
      <sec_outcome>Quality of Life. Timepoint: Before the intervention, 1 month, 3 months and 6 months after the end of the intervention. Method of measurement: Knee injury and Osteoarthritis Outcome Score (KOOS).</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Artesh University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-04-13</approval_date>
        <contact_name>Ethics committee of Artesh University of Medical Sciences</contact_name>
        <contact_address>Emam Reza Hospital , Etemadzade Ave. , West Fametemi Blvd. Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
